Company Overview

Update
Founded:
2001
Headquarters:
Ghent/Zwijnaarde
IPO:
Went Public on Nov 16, 2007
Stock:
EBR:ABLX
Categories:
Biotechnology

Ablynx is a biopharmaceutical company engaged in the discovery and development of nanobodies.

Description

Update

Ablynx is a biopharmaceutical company engaged in the discovery and development of NanobodiesĀ®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 projects in the pipeline and five Nanobodies in clinical development.

Current Team (14)

Update

Board Members and Advisors (3)

Update

Funding Rounds (1) - $41.40M

Update

Offices/Locations (1)

Update
  • Office

    Technologiepark 21

    Ghent/Zwijnaarde, 9052

    BEL

Images (1)

Update
  • 5d910e6e032d6a3cadc5d2bdff446cb8